Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma...

Full description

Saved in:
Bibliographic Details
Main Authors: Susan M. O’Brien, Jennifer R. Brown, John C. Byrd, Richard R. Furman, Paolo Ghia, Jeff P. Sharman, William G. Wierda
Format: article
Language:EN
Published: Frontiers Media S.A. 2021
Subjects:
acalabrutinib
adverse events
Bruton tyrosine kinase inhibitor
chronic lymphocytic leukemia
ibrutinib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/b1b57d9d157d496799b9fdf515094b55
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/b1b57d9d157d496799b9fdf515094b55

Similar Items